<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6534195\results\search\disease\results.xml">
  <result pre="(hazard ratio [HR], 0.24; 95% confidence interval [CI], .14–.44) or" exact="influenza" post="virus (HR, 0.52; 95% CI, .38–.73) conferred relative protection"/>
  <result pre="be protected against subsequent infection with adenovirus, coronavirus, enterovirus/rhinovirus, and" exact="influenza" post="virus (P = .062–.093), while men with influenza virus–positive"/>
  <result pre="enterovirus/rhinovirus, and influenza virus (P = .062–.093), while men with" exact="influenza" post="virus–positive FRI episodes tended be protected against subsequent infection"/>
  <result pre="protected against subsequent infection with adenovirus (P = .044) and" exact="influenza" post="virus (P = .081). Conclusion Prior adenovirus or influenza"/>
  <result pre="and influenza virus (P = .081). Conclusion Prior adenovirus or" exact="influenza" post="virus infection conferred cross-protection against subsequent FRI episodes relative"/>
  <result pre="viruses. As previously reported, the rollout of routine trivalent seasonal" exact="influenza" post="vaccination in the Singapore Armed Forces was accompanied by"/>
  <result pre="accompanied by a dramatic decline in the incidence of laboratory-confirmed" exact="influenza" post="virus infections but a much less noticeable decrease in"/>
  <result pre="data, to account for some degree of replacement for the" exact="influenza" post="virus infections averted through vaccination [15]. In this article,"/>
  <result pre="15 December 2009 and 31 December 2014, during which inactivated" exact="influenza" post="vaccine was routinely administered to recruits who did not"/>
  <result pre="did not have any contraindications. This was initially a monovalent" exact="influenza" post="vaccine (MIV) containing only 2009 pandemic influenza A(H1N1) virus"/>
  <result pre="initially a monovalent influenza vaccine (MIV) containing only 2009 pandemic" exact="influenza" post="A(H1N1) virus (A[H1N1]pdm09), for recruits who enlisted between 11"/>
  <result pre="4 October 2010. The MIV was superseded by a trivalent" exact="influenza" post="vaccine (TIV) that included A(H1N1)pdm09, for recruits who enlisted"/>
  <result pre="C, Levels within multilevel analysis. AdV, adenovirus; CoV, coronavirus; FluV," exact="influenza" post="virus; hMPV, human metapneumovirus; NA, not applicable; RSV, respiratory"/>
  <result pre="and other CoVs; enteroviruses and rhinoviruses (ERVs); human metapneumovirus (hMPV);" exact="influenza" post="virus (FluV)—influenza A(H3N2) virus, 2009 pandemic influenza A(H1N1) virus"/>
  <result pre="human metapneumovirus (hMPV); influenza virus (FluV)—influenza A(H3N2) virus, 2009 pandemic" exact="influenza" post="A(H1N1) virus (A[H1N1]pdm09), influenza A(H1N1) virus, influenza A virus–positive"/>
  <result pre="virus (FluV)—influenza A(H3N2) virus, 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09)," exact="influenza" post="A(H1N1) virus, influenza A virus–positive samples for which the"/>
  <result pre="virus, 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09), influenza A(H1N1) virus," exact="influenza" post="A virus–positive samples for which the subtype was undetermined,"/>
  <result pre="A virus–positive samples for which the subtype was undetermined, and" exact="influenza" post="B virus; human parainfluenza virus (hPIV)—types 1–4; and respiratory"/>
  <result pre="and ethnicity, type of BMT intake, history of smoking and" exact="asthma" post="(including childhood asthma), and receipt of influenza vaccine before"/>
  <result pre="of smoking and asthma (including childhood asthma), and receipt of" exact="influenza" post="vaccine before the FRI episode. Assessment of whether the"/>
  <result pre="years), and 99.9% were male. A total of 83.6% received" exact="influenza" post="vaccine in the past 1 year (with only 113"/>
  <result pre="1.95 (1.18–3.25)  Current 1253 120 (9.6) 1.48 (1.19–1.85) History of" exact="asthma" post=" No 4340 326 (7.5) Reference .812  Yes 1337 97"/>
  <result pre=" Yes 1337 97 (7.3) .08 (.07–.09) Influenza vaccinationc  No recent" exact="influenza" post="vaccination 930 97 (10.4) Reference .003  MIV for A(H1N1)pdm09"/>
  <result pre="TIV 47 3 (6.4) .59 (.18–1.92) Abbreviations: A(H1N1)pdm09, 2009 pandemic" exact="influenza" post="A(H1N1) virus; BMT, basic military training; CI, confidence interval;"/>
  <result pre="virus; BMT, basic military training; CI, confidence interval; MIV, monovalent" exact="influenza" post="vaccine; OR, odds ratio; TIV, trivalent influenza vaccine. aBy"/>
  <result pre="interval; MIV, monovalent influenza vaccine; OR, odds ratio; TIV, trivalent" exact="influenza" post="vaccine. aBy the Fisher exact test, comparing participants with"/>
  <result pre="870 [14.2%], including 138, 137, and 568 positive for A(H1N1)pdm09," exact="influenza" post="A(H3N2) virus, and influenza B virus, respectively), AdV (in"/>
  <result pre="137, and 568 positive for A(H1N1)pdm09, influenza A(H3N2) virus, and" exact="influenza" post="B virus, respectively), AdV (in 677 [11.0%], including 121"/>
  <result pre="0 (0.0)a Abbreviations: AdV, adenovirus; CoV, coronavirus; ERV, enterovirus/rhinovirus; FluV," exact="influenza" post="virus; hMPV, human metapneumovirus; hPIV, human parainfluenza virus; RSV,"/>
  <result pre="a sharp decline following routine administration of TIV. However, considerable" exact="influenza" post="A(H3N2) virus and influenza B virus activity was observed"/>
  <result pre="routine administration of TIV. However, considerable influenza A(H3N2) virus and" exact="influenza" post="B virus activity was observed from April 2013 through"/>
  <result pre="B and D, Distribution of FRI episodes due to any" exact="influenza" post="virus, 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09), influenza A(H3N2)"/>
  <result pre="of FRI episodes due to any influenza virus, 2009 pandemic" exact="influenza" post="A(H1N1) virus (A[H1N1]pdm09), influenza A(H3N2) virus, and influenza B"/>
  <result pre="to any influenza virus, 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09)," exact="influenza" post="A(H3N2) virus, and influenza B virus, by calendar time"/>
  <result pre="2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09), influenza A(H3N2) virus, and" exact="influenza" post="B virus, by calendar time (B) and week after"/>
  <result pre="BMT enlistment (D). Gray shading denotes the period when trivalent" exact="influenza" post="vaccine was routinely administered to incoming recruits. Prior Infection"/>
  <result pre="virus. B, Exposure status for adenovirus. C, Exposure status for" exact="influenza" post="virus. P values were calculated by log-rank tests to"/>
  <result pre="AdV, adenovirus; CI, confidence interval; CoV, coronavirus; ERV, enterovirus/rhinovirus; FluV," exact="influenza" post="virus; HR, hazard ratio; hMPV, human metapneumovirus; hPIV, human"/>
  <result pre="BMT intake, age, ethnicity, smoking history, history of asthma, and" exact="influenza" post="vaccination. cNot adjusted for FRI incidence rate by time"/>
  <result pre="infection. The observation of influenza’s protection against subsequent episodes of" exact="influenza" post="(mostly due to other types/subtypes in our data, in"/>
  <result pre="interference after accounting for seasonal factors, suggesting that epidemics of" exact="influenza" post="virus and rhinovirus infection tend to shift the timing"/>
  <result pre="inversely associated with the probability of observing adenovirus [12] and" exact="influenza" post="virus infections, with the latter 2 viral infections framed"/>
  <result pre="weak, time-limited protection, with the stronger effects from adenovirus and" exact="influenza" post="virus becoming apparent when aggregating data over the full"/>
  <result pre="to explain the extent of cross-protection observed with adenovirus and" exact="influenza" post="virus infections relative to other FRI episodes. Other proposed"/>
  <result pre="suspected on the basis of time-series analyses, such as how" exact="influenza" post="epidemics potentially delay RSV epidemics [8, 25]. They also"/>
  <result pre="for mechanisms on common factors induced by both adenovirus and" exact="influenza" post="virus. Notably, our previous studies suggest that infections with"/>
  <result pre="relative cross-protection against subsequent FRI episodes conferred by adenovirus and" exact="influenza" post="virus infections. In summary, our study demonstrated broad-based viral"/>
  <result pre="a population of military recruits. Infections from the adenovirus and" exact="influenza" post="virus families conferred significant cross-protective effects against subsequent FRI"/>
  <result pre="Clin1988; 38:280–90.2458172 4.ChanKF, CarolanLA, KorenkovD, et al.Investigating viral interference between" exact="influenza" post="a virus and human respiratory syncytial virus in a"/>
  <result pre="5.Costa-HurtadoM, AfonsoCL, MillerPJ, et al.Virus interference between H7N2 low pathogenic" exact="avian influenza" post="virus and lentogenic Newcastle disease virus in experimental co-infections"/>
  <result pre="AfonsoCL, MillerPJ, et al.Virus interference between H7N2 low pathogenic avian" exact="influenza" post="virus and lentogenic Newcastle disease virus in experimental co-infections"/>
  <result pre="infections and viral hierarchy are determinants of viral interference following" exact="influenza" post="virus infection in a ferret model. J Infect Dis2015;"/>
  <result pre="One2015; 10:e0125447.25928217 8.AstenL van, BijkerkP, FanoyE, et al.Early occurrence of" exact="influenza" post="A epidemics coincided with changes in occurrence of other"/>
  <result pre="9.ZhengX, SongZ, LiY, ZhangJ, WangX-LPossible interference between seasonal epidemics of" exact="influenza" post="and other respiratory viruses in Hong Kong, 2014–2017. BMC"/>
  <result pre="OttmannM, DuchampMB, et al.Rhinoviruses delayed the circulation of the pandemic" exact="influenza" post="A (H1N1) 2009 virus in France. Clin Microbiol Infect2010;"/>
  <result pre="Microbiol Infect2010; 16:326–9.20121829 14.HoHP, ZhaoX, PangJ, et al.Effectiveness of seasonal" exact="influenza" post="vaccinations against laboratory-confirmed influenza-associated infections among Singapore military personnel"/>
  <result pre="ChenMI-C, et al.Rate of decline of antibody titers to pandemic" exact="influenza" post="A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays"/>
  <result pre="BMC Infect Dis2014; 14:414.25066592 18.YoungB, SadaranganiS, JiangL, Wilder-SmithA, ChenMIDuration of" exact="influenza" post="vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of"/>
  <result pre="19.YoungB, ZhaoX, CookAR, ParryCM, Wilder-SmithA, I-ChengMCDo antibody responses to the" exact="influenza" post="vaccine persist year-round in the elderly? A systematic review"/>
  <result pre="35:212–21.27939013 20.GohEH, JiangL, HsuJP, et al.Epidemiology and relative severity of" exact="influenza" post="subtypes in Singapore in the post-pandemic period from 2009"/>
  <result pre="2010. Clin Infect Dis2017; 65:1905–13.29028950 21.Schultz-CherrySViral interference: the case of" exact="influenza" post="viruses. J Infect Dis2015; 212:1690–1.25943204 22.TakedaK, AkiraSToll-like receptors. Curr"/>
  <result pre="One2016; 11:e0155589.27196110 25.AnestadGInterference between outbreaks of respiratory syncytial virus and" exact="influenza" post="virus infection. Lancet1982; 1:502. 26.LauY-F, KohW-HV, KanC, et al.Epidemiologic"/>
 </snippets>
</snippetsTree>
